Sustained targeting of Bcr-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy

Biomaterials

Volumn 32, Issue 24, 2011, Pages 5643-5662

  Acharya, Sarbari ^a   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Apoptosis; Chronic myeloid leukemia; Dual drug; Signaling pathway; Sustain release; Synergistic action

Indexed keywords

APOPTOSIS; CHRONIC MYELOID LEUKEMIA; DUAL DRUG; SIGNALING PATHWAY; SUSTAIN RELEASE; SYNERGISTIC ACTION;

CELL CULTURE; CELL DEATH; DISEASE CONTROL; DISEASES; DRUG DELIVERY; DRUG INTERACTIONS; NANOPARTICLES; PIGMENTS; SIGNALING;

DRUG DOSAGE;

ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CASPASE 3; CASPASE 8; CUR 500; DOXORUBICIN; ETOPOSIDE; NANOPARTICLE; NUTLIN 3; PACLITAXEL; POLYGLACTIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; RAPAMYCIN; UNCLASSIFIED DRUG;

ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COMPETITIVE INHIBITION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG POTENTIATION; DRUG SCREENING; DRUG UPTAKE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; IC 50; LEUKEMIA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TARGET CELL DESTRUCTION; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DRUG SYNERGISM; HUMANS; LACTIC ACID; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE POTENTIAL, MITOCHONDRIAL; NANOPARTICLES; PACLITAXEL; POLYGLYCOLIC ACID; POLYMERASE CHAIN REACTION; SIROLIMUS;

EID: 79957890122     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.04.043     Document Type: Article

References (68)

1. McGahon A.J., Brown D.G., Martin S.J., Amarante-Mendes G.P., Cotter T.G., Cohen G.M., et al. Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: characterization of the apoptotic death. Cell Death Differ 1997, 4:95-104.
2. Grosveld G., Verwoerd T., van Agthoven T., de Klein A., Ramachandran K.L., Heisterkamp N., et al. The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. Mol Cell Biol 1986, 6:607-616.
3. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005, 5:172-183.
4. Cortez D., Reuther G., Pendergast A.M. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 1997, 15:2333-2342.
5. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
6. Salesse S., Verfaillie C.M. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene 2002, 21:8547-8559.
7. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. Eng Med 2001, 344:1031-1037.
8. Bhatia R., Holtz M., Niu N., Gray R., Snyder D.S., Sawyers C.L., et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003, 101:4701-4707.
9. Dai Y., Rahmani M., Pei X.Y., Dent P., Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 2004, 104:509-518.
10. Mow B.M., Chandra J., Svingen P.A., Hallgren C.G., Weisberg E., Kottke T.J., et al. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 2002, 99:664-671.
11. Lehar J., Krueger A.S., Avery W., Heilbut A.M., Johansen L.M., Price E.R., et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009, 27:659-666.
12. Perez-Caro M., Gutierrez-Cianca N., Gonzalez-Herrero I., Lopez-Hernandez I., Flores T., Orfao A., et al. Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice. Oncogene 2007, 26:1702-1713.
13. Rahmani M., Yu C., Dai Y., Reese E., Ahmed W., Dent P., et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 2003, 63:8420-8427.
14. Yu C., Rahmani M., Conrad D., Subler M., Dent P., Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003, 102:3765-3774.
15. Jakubowska J., Wasowska-Lukawska M., Czyz M. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis. Eur J Pharmacol 2008, 596:41-49.
16. Du Y., Wang K., Fang H., Li J., Xiao D., Zheng P., et al. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood 2006, 107:1582-1590.
17. Parveen S., Sahoo S.K. Polymeric nanoparticles for cancer therapy. J Drug Target 2008, 16:108-123.
18. Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003, 8:1112-1120.
19. Acharya S., Dilnawaz F., Sahoo S.K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 2009, 30:5737-5750.
20. Misra R., Sahoo S.K. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 2010, 39:152-163.
21. Sahoo S.K., Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2005, 2:373-383.
22. Das M., Sahoo S.K. Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy. Acta Biomater 2010, 7:355-369.
23. Mohanty C., Acharya S., Mohanty A.K., Dilnawaz F., Sahoo S.K. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond) 2010, 5:433-449.
24. Nam H.Y., Kwon S.M., Chung H., Lee S.Y., Kwon S.H., Jeon H., et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release 2009, 135:259-267.
25. Panyam J., Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(D, L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res 2003, 20:212-220.
26. Parveen S., Mitra M., Krishnakumar S., Sahoo S.K. Enhanced antiproliferative activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma cell line. Acta Biomater 2010, 6:3120-3131.
27. Vandana M., Sahoo S.K. Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials 2010, 31:9340-9356.
28. Prabha S., Zhou W.Z., Panyam J., Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm 2002, 244:105-115.
29. Misra R., Acharya S., Sahoo S.K. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today 2010, 15:842-850.
30. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2009, 75:1-18.
31. Singh A., Dilnawaz F., Mewar S., Sharma U., Jagannathan N.R., Sahoo S.K. Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and Hydrophilic anticancer drugs and MRI imaging for cancer therapy. ACS Appl Mater Interfaces 2011.
32. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001, 70:1-20.
33. Zhigaltsev I.V., Maurer N., Akhong Q.F., Leone R., Leng E., Wang J., et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release 2005, 104:103-111.
34. Jensen K.D., Nori A., Tijerina M., Kopeckova P., Kopecek J. Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J Control Release 2003, 87:89-105.
35. Meng W., Parker T.L., Kallinteri P., Walker D.A., Higgins S., Hutcheon G.A., et al. Uptake and metabolism of novel biodegradable poly (glycerol-adipate) nanoparticles in DAOY monolayer. J Control Release 2006, 116:314-321.
36. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb J 2002, 16:1217-1226.
37. Tomas B.J. Cell-cycle control during development: taking it up a notch. Dev Cell 2005, 8:451-452.
38. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat Med 2000, 6:513-519.
39. Vaux D.L., Korsmeyer S.J. Cell death in development. Cell 1999, 96:245-254.
40. Kantrow S.P., Piantadosi C.A. Release of cytochrome c from liver mitochondria during permeability transition. Biochem Biophys Re Commun 1997, 232:669-671.
41. Desagher S., Martinou J.C. Mitochondria as the central control point of apoptosis. Trends Cell Biol 2000, 10:369-377.
42. Wang X., Wang Y., Chen Z.G., Shin D.M. Advances of cancer therapy by nanotechnology. Cancer Res Treat 2009, 41:1-11.
43. Dilnawaz F., Singh A., Mohanty C., Sahoo S.K. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010, 31:3694-3706.
44. Ahsan F., Rivas I.P., Khan M.A. Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 2002, 79:29-40.
45. Hui R.C., Francis R.E., Guest S.K., Costa J.R., Gomes A.R., Myatt S.S., et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther 2008, 7:670-678.
46. Palama I.E., Leporatti S., de Luca E., Di Renzo N., Maffia M., Gambacorti-Passerini C., et al. Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells. Nanomedicine (Lond) 2010, 5:419-431.
47. Luo H., Li J., Chen X. Antitumor effect of N-succinyl-chitosan nanoparticles on K562 cells. Biomed Pharmacother 2009, 64:521-526.
48. Yang X., Koh C.G., Liu S., Pan X., Santhanam R., Yu B., et al. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm 2009, 6:221-230.
49. Al Alami O., Sammons J., Martin J.H., Hassan H.T. Divergent effect of taxol on proliferation, apoptosis and nitric-oxide production in MHH225 CD34-positive and U937 CD34-negative human leukemia cells. Leuk Res 1998, 22:939-945.
50. Haldar S., Basu A., Croce C.M. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997, 57:229-233.
51. Gangemi R.M., Santamaria B., Bargellesi A., Cosulich E., Fabbi M. Late apoptotic effects of taxanes on K562 erythroleukemia cells: apoptosis is delayed upstream of caspase-3 activation. Int J Cancer 2000, 85:527-533.
52. Jain T.K., Richey J., Strand M., Leslie-Pelecky D.L., Flask C.A., Labhasetwar V. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials 2008, 29:4012-4021.
53. Shapiro G.I., Harper J.W. Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 1999, 104:1645-1653.
54. Jordan M.A., Toso R.J., Thrower D., Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993, 90:9552-9556.
55. Donaldson K.L., Goolsby G.L., Kiener P.A., Wahl A.F. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 1994, 5:1041-1050.
56. Holstein S.A., Hohl R.J. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 2001, 1:141-149.
57. Kaufmann S.H., Hengartner M.O. Programmed cell death: alive and well in the new millennium. Trends Cell Biol 2001, 11:526-534.
58. Yang C.Z., Luan F.J., Xiong D.S., Liu B.R., Xu Y.F., Gu K.S. Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin. Zhongguo Yao Li Xue Bao 1995, 16:333-337.
59. Merimsky O., Gorzalczany Y., Sagi-Eisenberg R. Molecular impacts of rapamycin-based drug combinations: combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model. Int J Oncol 2007, 31:225-232.
60. Hu L., Hofmann J., Lu Y., Mills G.B., Jaffe R.B. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002, 62:1087-1092.
61. Page C., Lin H.J., Jin Y., Castle V.P., Nunez G., Huang M., et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000, 20:407-416.
62. Hahn M., Li W., Yu C., Rahmani M., Dent P., Grant S. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 2005, 4:457-470.
63. Blagosklonny M.V. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 2004, 23:2967-2975.
64. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
65. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
66. Chen B., Liang Y., Wu W., Cheng J., Xia G., Gao F., et al. Synergistic effect of magnetic nanoparticles of Fe(3)O(4) with gambogic acid on apoptosis of K562 leukemia cells. Int J Nanomedicine 2009, 4:251-259.
67. Nicholson D.W. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 1999, 6:1028-1042.
68. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 2003, 195:158-167.